UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Completed
Unique ID issued by UMIN UMIN000005108
Receipt No. R000006075
Scientific Title Pilot study of bevacizumab and irinotecan in children with recurrent or refractory solid tumors.
Date of disclosure of the study information 2011/02/19
Last modified on 2012/02/22

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Pilot study of bevacizumab and irinotecan in children with recurrent or refractory solid tumors.
Acronym Pilot study of bevacizumab in children with recurrent/refractory solid rumors.
Scientific Title Pilot study of bevacizumab and irinotecan in children with recurrent or refractory solid tumors.
Scientific Title:Acronym Pilot study of bevacizumab in children with recurrent/refractory solid rumors.
Region
Japan

Condition
Condition Recurrent or refractory solid tumors
Classification by specialty
Hematology and clinical oncology Pediatrics
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 Determining the dose-limiting toxicities (DLTs) and estimating the maximum-tolerated dose (MTD) of Bevacizumab and irinotecan.
Basic objectives2 Safety
Basic objectives -Others
Trial characteristics_1 Confirmatory
Trial characteristics_2
Developmental phase Phase I

Assessment
Primary outcomes Determine the DLTs.
Key secondary outcomes Estimate the rate of treatment-related toxicity.

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 Bevacizumab and irinotecan are administered i.v., once every 2 weeks: days 1, 15 and 29 of a 6-week cycle. Irinotecan is administered over 90 min before the bevacizumab infusion. Bevacizumab is administered 60-90 min. Treatment repeats every 2 weeks for up to 3 cycles in the absence of unacceptable toxicity or tumor progression.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
0 years-old <=
Age-upper limit
40 years-old >=
Gender Male and Female
Key inclusion criteria Diagnosis of pediatric solid tumors or brain tumors.
Recurrent, progressive, or refractory disease (must have received prior therapy)
No evidence of CNS hemorrhage within the past 2 weeks.
At least 3 weeks since prior anticancer chemotherapy.
More than 7 days since prior minor surgery, and at least 6 weeks since prior major surgery.
At least 3 months since prior autologous bone marrow or stem cell transplantation.
More than 12 weeks since prior irradiation.
No concurrent therapeutic anticoagulation.
No concurrent non-steroidal anti-inflammatory drugs.
Karnofsky performance status (PS) 50-100%.
At least 72 hours since prior G-CSF.
Absolute neutrophil count >500/mm3
Platelet count >75000/mm3
ALT and AST < 2.5 times ULN
Bilirubin < 1.5 mg/dl
No uncontrolled systemic hypertension.
No stroke, myocardial infarction, unstable angina, or peripheral vascular disease.
No evidence of bleeding diathesis, or coagulopathy.
No significant traumatic injury within the past 6 weeks.
No abdominal fistula or gastrointestinal perforation within the past 6 months.
No pregnant or nursing.
Key exclusion criteria Has a double cancer.
Has a cardiac disease for which treatment is necessary.
Has a psychosis or mental disorder.
Target sample size 12

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Junichi Hara
Organization Osaka City General Hospital
Division name Pediatric Hematology/Oncology
Zip code
Address 2-13-22, Miyakojima-hondori, Miyakojima-ku, Osaka, Japan
TEL
Email

Public contact
Name of contact person
1st name
Middle name
Last name Keiko Okada
Organization Osaka City General Hospital
Division name Pediatric Hematology/Oncology
Zip code
Address
TEL
Homepage URL
Email keik-okada@hospital.city.osaka.jp

Sponsor
Institute Osaka City General Hospital
Institute
Department

Funding Source
Organization Ministry of Health
Organization
Division
Category of Funding Organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2011 Year 02 Month 19 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2009 Year 02 Month 27 Day
Date of IRB
Anticipated trial start date
2009 Year 02 Month 01 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2011 Year 02 Month 19 Day
Last modified on
2012 Year 02 Month 22 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006075

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.